Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 19/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5576887 | 0.95 | KDM4E (0.45) | KDM4EALDH1A1GAAMAPK1TDP1 | |
| SCHEMBL5233243 | 0.85 | PLA2G2A (0.38) | ALDH1A1GAAPOLBMEN1KMT2A | |
| Oxalic Acid SCHEMBL5577086 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL5576340 | 0.81 | CCR2 (0.46) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL5235402 | 0.81 | PTGS1 (0.36) | KDM4EGAATDP1POLBKMT2A | |
| SCHEMBL5576633 | 0.79 | CCR2 (0.41) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5576873 | 0.75 | DPP4 (0.36) | ALDH1A1GAAPOLBMEN1KMT2A | |
| SCHEMBL5233440 | 0.72 | L3MBTL1 (0.39) | ALDH1A1GAALMNA | |
| SCHEMBL5577098 | 0.72 | ALOX5AP (0.39) | KDM4EALDH1A1MAPK1CYP2D6 | |
| SCHEMBL5576476 | 0.72 | DNMT1 (0.39) | KDM4EPOLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | KDM4E 2749/4885ALDH1A1 2961/4885GAA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.